Formosa Pharmaceuticals News
Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers
Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers TSY-110 is positioned to become the first biosimilar alternative …
Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following …
Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting
Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting TAIPEI, TAIWAN – May 22, 2026 – Formosa Pharmaceuticals, Inc. announces that its …
Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases
Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases SINGAPORE / TAIPEI — April 30, 2026 – …
Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery TAIPEI …
Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following …
